Nanomerics Ltd is a speciality pharmaceutical company based in London, UK. Nanomerics was spun out of University College London, a top 20 global university and was founded to commercialise the Molecular Envelope Technology (MET) developed in the UK academic sector. Nanomerics’ MET enables the transport of drugs across key biological epithelial barriers and this allows Nanomerics to create uniquely differentiated products, underpinned by high quality science. Nanomerics’ MET recently won first prize in the prestigious Royal Society of Chemistry Emerging Technologies competition.
Nanomerics has out-licensed NM127, an enkephalin-based pain asset to Virpax Pharmaceuticals and NM133, a dry-eye asset to Iacta Pharmaceuticals. Both of these assets are powered by Nanomerics’ MET. Nanomerics has a pipeline of assets that have the potential to offer significant patient benefit. Nanomerics is committed to a world where patients receive the best medicines possible for their conditions.
National Institute of Health Research (NIHR)
The National Institute for Health Research (NIHR) is unique, it is the worlds most integrated research network and provides a gateway for you to carry out your clinical research and technology evaluation in the NHS.
We are a government funded organisation, founded in 2006 to improve the health and wealth of the nation, we work with a diverse range of industry sectors, including diagnostics, medical technology, biopharmaceutical and CROs, as well as with associated industries such as digital, design and artificial intelligence.
We offer a free of charge, robust feasibility service to all companies that have eligible study proposals. This includes an expert protocol/synopsis review, providing national level feasibility of the "doability" and compatibility of the trial in the NHS. Along with 2 site level feasibility services, 1 of which identifies potential centers to run your trial, all done within 3 weeks. We also provide support through the set up and recruitment phase to ensure your study is set up swiftly and delivers the target number of patients on time.
We have helped demonstrate that the UK is globally competitive in speed of study set up by recruiting 28 global firsts into commercial trials last year. We also supported the recruitment of over 870,000 participants onto clinical trials in the last financial year.
We have worked with and provided support to over 1300 different companies over the years and we are looking forward to meeting new ones BIO Europe to whom we can support.